The Relative Strength (RS) Rating for Takeda Pharmaceutical ADR entered a higher percentile Thursday, as it got a lift from 66 to 73.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks typically have an RS Rating north of 80 as they begin their largest runs. See if Takeda Pharmaceutical ADR can continue to show renewed price strength and clear that threshold.
Takeda Pharmaceutical ADR broke out earlier, but has fallen back below the prior 15.53 entry from a cup without handle. If a stock you're tracking clears a buy point then declines 7% or more below the original entry price, it's considered a failed base. Wait for the stock to set up and breakout from a new chart pattern and buy point. Also keep in mind that the most recent pattern is a later-stage base, and those involve more risk.
Top and bottom line growth moved higher last quarter. Earnings were up -4%, compared to -33% in the prior report. Revenue increased from 1% to 2%.
The company earns the No. 13 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Grifols ADR and Novartis ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
